Perspectives on Practice Changing Research 2024
Moderated by Dr. Hertzel Gerstein, this accredited online symposium features a review of the key scientific developments in endocrinology and diabetes over the past year. Our faculty will synthesize and discuss within the Canadian context research from major conferences and papers.
Topics covered:
• Mythbusting about GLP1 receptor agonists
• The complex diagnostic puzzle of ACTH-dependent hypercortisolism
• SGLT2 inhibitors and new-onset diabetes
• Surgery vs. mineralocorticoid receptor antagonists for primary aldosteronism patients
1. Review and synthesize key scientific developments in diabetes and endocrinology over the past year
2. Evaluate the relevance and implications for diabetes management within a Canadian context
3. Identify important elements of emerging research that can be applied to clinical practice
Biography:
Dr. Christopher Tran is the program director for the Endocrinology and Metabolism residency training program at the University of Ottawa. He is an assistant professor at the University of Ottawa and received Educator of the Year (Preclerkship) and the 2022 Canadian Association Medical Education Certificate of Merit awards for his contributions to medical education.
Conflicts of Interest:
I do not have a relationship with a for-profit and/or not-for-profit organization to disclose.
Biography:
Clinical endocrinologist at the CIUSSS de l’Estrie-CHUS in Sherbrooke, Quebec, since 2019. He has expertise in adrenal disorders and Cushing’s syndrome. He is also involved in clinical research focusing mainly on primary aldosteronism and Cushing’s syndrome. He is involved in 2 international adrenal research groups, the ENSAT and the A5.
Conflicts of Interest:
Direct financial payments including receipt of honoraria – honoraria from Recordati rare disease, GlaxoSmithKline
Membership on advisory boards – Medunik Canada
Clinical trials – PI, Astra Zeneca, Spruce biosciences; Sub-I, Novo Nordisk
Biography:
Dr Caroline K Kramer is an Associate Professor, Endocrinologist, and Clinician-Scientist at the University of Toronto, Division of Endocrinology and Leadership Sinai Centre for Diabetes/Mount Sinai Hospital.
Her clinical research work has focused on the pathophysiology and risk factors for the development of type 2 diabetes mellitus particularly the interaction between obesity and diabetes, risk factors for cardiovascular disease in individuals with metabolic abnormalities, and strategies for the treatment of type 2 diabetes (including lifestyle interventions such as intermittent fasting strategies and pharmacological approaches).
To date, her research has yielded more than 135 original peer-reviewed publications including first-authorship publications in high-impact general medical journals such as Annals of Internal Medicine and British Medical Journal, and top subspecialty journals in the field of diabetes and endocrinology including Diabetes, Diabetes Care and Journal of Clinical Endocrinology and Metabolism.
She has received the Diabetes Canada Clinician-Scientist award (2016-2021), Banting and Best New Investigator award 2015/2016 and her research has been funded by the Canadian Institute of Health Research (CIHR), Diabetes Canada, and Heart and Stroke Foundation of Canada.
Conflicts of Interest:
Funded Grants – Boehringer Ingelheim, investigator-initiated study
Biography:
Dr. Hertzel C. Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research. He is also Director of the Division of Endocrinology & Metabolism, Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute. He has received several honors including the Canadian Diabetes Association’s Young Scientist Award (1999), Frederick G. Banting award (1999), Charles H. Best award (2007) and Lifetime Achievement Award (2012). Dr. Gerstein has designed and led many large simple international cardiovascular outcome trials in people with diabetes globally, and developed the concept of dysglycemia as an important risk factor for many of the serious health outcomes that afflict people with an elevated glucose level regardless of diabetes status. His research spans over 50 countries, and has been funded by the Canadian Institutes of Health Research, the National Institutes of Health, the Heart and Stroke Foundation, the Canadian Diabetes Association and Industry. Dr. Gerstein has published more than 300 papers, editorials and commentaries, mainly on diabetes-related issues.
Conflicts of Interest:
Membership on advisory boards or speakers’ bureaus – Sanofi, Lilly, Boehringer Ingelheim, DKSH, Zuellig, Roche – speaker.
Sanofi, Lilly, Novo Nordisk, Abbott, Boehringer Ingelheim, Pfizer, Kowa, Hanmi – Consulting.
Lilly, Sanofi, Novo Nordisk, Merck, AstraZeneca – grants to his institution for research.
Novo Nordisk
Eli Lilly
